Acelyrin Says Late-Stage Izokibep Trial Shows Statistically Significant Results
Express News | ACELYRIN, Inc. Announces Positive Results From Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to Be Highlighted in Late-Breaking Oral Presentation at Eadv 2024
ACELYRIN, INC. Announces Positive Results From Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to Be Highlighted in Late-Breaking Oral Presentation at EADV 2024
Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc
Acelyrin Announced That Data From Its Phase 1/2 Clinical Trial Of Lonigutamab In Thyroid Eye Disease Will Be Shared At The Annual Meeting Of The European Society Of Ophthalmic Plastic And Reconstructive Surgery
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Maintains Target Price $6
Morgan Stanley analyst Vikram Purohit maintains $Acelyrin(SLRN.US)$ with a hold rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 33.6% and a
Express News | ACELYRIN Inc : Morgan Stanley Cuts Target Price to $6 From $13
ACELYRIN Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley Maintains Equal-Weight on Acelyrin, Lowers Price Target to $6
Morgan Stanley Maintains Acelyrin(SLRN.US) With Hold Rating, Cuts Target Price to $6
Morgan Stanley analyst Vikram Purohit maintains $Acelyrin(SLRN.US)$ with a hold rating, and adjusts the target price from $13 to $6.According to TipRanks data, the analyst has a success rate of 33.6%
ACELYRIN, INC.: Hold Rating Maintained Amid Strategic Pipeline Shift and Extended Cash Runway
HC Wainwright & Co. Downgrades Acelyrin to Neutral, Lowers Price Target to $6
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
ACELYRIN Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Overweight on Acelyrin, Lowers Price Target to $20
Acelyrin Analyst Ratings
Acelyrin Shares Slide on Layoffs, Portfolio Refocus
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $6 to $20
On Aug 14, major Wall Street analysts update their ratings for $Acelyrin(SLRN.US)$, with price targets ranging from $6 to $20.Wells Fargo analyst Derek Archila maintains with a buy rating, and